Comparative pharmacology of H1 antihistamines: Clinical relevance

American Journal of Medicine

Volumn 113, Issue 9 SUPPL. 1, 2002, Pages 38-46

  Simons, F Estelle R ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIVASTINE; ANTIHISTAMINIC AGENT; CETIRIZINE; DESLORATADINE; EBASTINE; FEXOFENADINE; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; PROTEIN; HISTAMINE H1 RECEPTOR ANTAGONIST;

CONCENTRATION (PARAMETERS); DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG USE; GROUPS BY AGE; HUMAN; KIDNEY DISEASE; LIVER DYSFUNCTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; URTICARIA; COMPARATIVE STUDY; HYPERSENSITIVITY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPERSENSITIVITY;

EID: 0037122434     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(02)01436-5     Document Type: Review

References (28)

1. Kaufman D.W., Kelly J.P., Rosenberg L., Anderson T.E., Mitchell A.A. Recent patterns of medication use in the ambulatory adult population of the United States the Slone survey . JAMA. 287:2002;337-344.
2. 1-receptor antagonist drugs. N Engl J Med. 330:1994;1663-1670.
3. Mycek MJ, Harvey RA, Champe PC. Absorption, distribution, and elimination of drugs. In: Mycek MJ, Harvey RA, Champe PC, eds. Pharmacology, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000:1-15.
4. 1-Receptor Antagonists in Allergic Disease, 2nd ed. New York: Marcel Dekker, 2002:141-178.
5. 1-antihistamines inverse agonism, anti-inflammatory actions and cardiac effects . Clin Exp Allergy. 32:2002;489-498.
6. 1-antihistamines on adhesion molecules a possible rationale for long-term treatment . Clin Exp Allergy. 29:(suppl 3):1999;49-53.
7. Brogden R.N., McTavish D. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs. 41:1991;927-940.
8. Spencer C.M., Faulds D., Peters D.H. Cetirizine A reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders . Drugs. 46:1993;1055-1080.
9. McClellan K., Jarvis B. Desloratadine. Drugs. 61:2001;789-796.
10. Hurst M., Spencer C.M. Ebastine. An update of its use in allergic disorders. Drugs. 59:2000;981-1006.
11. Simpson K., Jarvis B. Fexofenadine. A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs. 59:2000;301-321.
12. Xyzal Product Monograph. UCB Pharma, Brussels, Belgium, 2001.
13. Haria M., Fitton A., Peters D.H. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 48:1994;617-637.
14. Simons F.E.R. Mizolastine antihistaminic activity from preclinical data to clinical evaluation . Clin Exp Allergy. 29:(suppl 1):1999;3-8.
15. 1-receptor antagonists . Clin Drug Invest. 21:2001;587-596.
16. Hindmarch I., Shamsi Z., Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system a double-blind, placebo-controlled study in healthy volunteers . Clin Exp Allergy. 32:2002;133-139.
17. Mason J., Reynolds R., Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy. 29:(suppl 3):1999;163-170.
18. Simons F.E.R., Bergman J.N., Watson W.T.A., Simons K.J. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol. 98:1996;1062-1064.
19. Mesnil F., Mentre F., Dubruc C., Thenot J.P., Mallet A. Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method. J Pharmacokinet Biopharm. 26:1998;133-161.
20. Day J.H., Briscoe M., Rafeiro E., Chapman P., Kramer B. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis confirmation of a test system . Ann Allergy Asthma Immunol. 87:2001;474-481.
21. 2-macroglobulin into human nasal airways. Clin Exp Allergy. 27:1997;438-444.
22. Grant J.A., Riethuisen J.M., Moulaert B., DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects . Ann Allergy Asthma Immunol. 88:2002;190-197.
23. Howarth P.H., Stern M.A., Roi L., Reynolds R., Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 104:1999;927-933.
24. van Cauwenberge P., Juniper E.F. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg, and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 30:2000;891-899.
25. Finn A.F. Jr, Kaplan A.P., Fretwell R., Qu R., Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 104:1999;1071-1078.
26. 1-receptor antagonists in skin and serum. J Allergy Clin Immunol. 95:1995;759-764.
27. 1-receptor antagonists. J Allergy Clin Immunol. 107:2001;526-530.
28. 1-antihistamines in the skin. J Allergy Clin Immunol. 2002;110:777-783.